Ixekizumab resolves nail psoriasis better than adalimumab in PsA Presented ByProf. Dennis McGonagle, University of Leeds, United Kingdom TrialPhase 4, SPIRIT-H2H ConferenceACR 2023 1 December, 2023 12:36
IV secukinumab safe and effective for long-term treatment of active PsA Presented ByProf. Iain McInnes, University of Glasgow, Scotland TrialFUTURE 2-5 ConferenceACR 2023 1 December, 2023 12:04
Short-term glucocorticoid use increases the risk of MACE Presented ByDr Beth Wallace, University of Michigan, MI, USA ConferenceACR 2023 1 December, 2023 12:32
Positive efficacy and safety results of novel BlyS/APRIL inhibitor in RA Presented ByProf. Li Wang, Peking Union Medical College Hospital, China TrialPhase 3 ConferenceACR 2023 1 December, 2023 12:27
Is split-dose methotrexate superior to single-dose methotrexate in RA? Presented ByDr Varun Dhir TrialSMART ConferenceACR 2023 1 December, 2023 12:11
Baricitinib superior to TNFi in patients with RA who failed csDMARDs Presented ByDr Mart van der Laar, University of Twente, The Netherlands TrialPerfectRA ConferenceACR 2023 1 December, 2023 11:40
Encouraging results of afimetoran in participants with cutaneous lupus Presented ByDr Fareeda Hosein, Bristol Myers Squibb, NJ, USA TrialPhase 1 ConferenceACR 2023 1 December, 2023 12:24
CAR-T cell therapy results in sustained lupus remission Presented ByDr Georg Schett, University Hospital Erlangen, Germany ConferenceACR 2023 1 December, 2023 12:06
Repeat steroid injection in knee osteoarthritis possibly beneficial Presented ByProf. David Hunter, University of Sydney, Australia TrialPhase 3 ConferenceACR 2023 1 December, 2023 12:30
Romosozumab tops denosumab in glucocorticoid users with high fracture risk Presented ByDr Chi Chiu Mok, Tuen Mun Hospital, Hong Kong, China ConferenceACR 2023 1 December, 2023 12:08
Ixekizumab resolves nail psoriasis better than adalimumab in PsA Presented ByProf. Dennis McGonagle, University of Leeds, United Kingdom TrialPhase 4, SPIRIT-H2H ConferenceACR 2023 1 December, 2023 12:36
IV secukinumab safe and effective for long-term treatment of active PsA Presented ByProf. Iain McInnes, University of Glasgow, Scotland TrialFUTURE 2-5 ConferenceACR 2023 1 December, 2023 12:04
Apremilast in early oligoarticular PsA: phase 4 study results Presented ByDr Philip Mease, University of Washington, WS, USA TrialPhase 4, FOREMOST ConferenceACR 2023 1 December, 2023 12:03
Novel selective URAT1 inhibitor shows promise in gout Presented ByProf. Robert Keenan, Duke University School of Medicine, NC, USA TrialPhase 2 ConferenceACR 2023 1 December, 2023 12:18
Incidence and risk factors for new-onset interstitial lung disease Presented ByDr Liubov Petelytska, Bogomolets National Medical University, Kyiv, Ukraine TrialEUSTAR ConferenceACR 2023 1 December, 2023 12:20
No need to avoid TNF inhibitors in RA-ILD? Presented ByDr Bryant England, Unversity of Nebraska Medical Center, USA TrialPhase 4 ConferenceACR 2023 1 December, 2023 11:41
Reduced-dose glucocorticoids in GPA and MPA increase mortality Presented ByDr Sophie Nagle, Paris-Saclay University, Paris TrialPEXIVAS ConferenceACR 2023 1 December, 2023 11:55
